- Trials with a EudraCT protocol (20)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
20 result(s) found for: Colposcopy.
Displaying page 1 of 1.
EudraCT Number: 2012-004518-32 | Sponsor Protocol Number: ITIC2-2.3 | Start Date*: 2013-02-13 |
Sponsor Name:Medizinische Universität Wien | ||
Full Title: ITIC2 Trial - Topical Imiquimod versus Conization to Treat Cervical Intraepithelial Neoplasia: Randomised Controlled, Non-inferiority Trial | ||
Medical condition: In this randomized controlled, multi-center trial we will investigate the non-inferiority of a topical IMQ treatment compared to surgical standard treatment in selected patients diagnosed with CIN ... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2008-004604-31 | Sponsor Protocol Number: PCCE201/08 | Start Date*: 2008-10-28 | |||||||||||
Sponsor Name:Photocure ASA | |||||||||||||
Full Title: A randomized phase II dose-finding study of hexaminolevulinate (HAL) photodynamic therapy (PDT) in patients with low-grade cervical intraepithelial neoplasia. | |||||||||||||
Medical condition: Low grade cervical intraepithelial neoplasia (CIN) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000269-42 | Sponsor Protocol Number: 1-23-456 | Start Date*: 2022-06-08 | |||||||||||
Sponsor Name:Randers Regional Hospital, Department of Gynecology and Obstetrics | |||||||||||||
Full Title: Improving diagnostics in cervical dysplasia | |||||||||||||
Medical condition: Abnormal cervical cells | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-008124-33 | Sponsor Protocol Number: 112024 | Start Date*: 2009-10-07 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase IIIb, open, multi centre gynaecological extension study for follow-up of a subset of 580299/008 study subjects who were either cervical cytology negative and oncogenic HPV positive or pregn... | ||
Medical condition: GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine is indicated in females from 10 years of age onwards for the prevention of cervical cancer (squamous-cell carcinoma and adenocarcinoma) by protecting ... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: FI (Completed) ES (Completed) DE (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-023903-91 | Sponsor Protocol Number: PCCE203/10 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Photocure ASA | |||||||||||||
Full Title: A randomized phase II dose-finding study of hexaminolevulinate (HAL) photodynamic therapy (PDT) in patients with low/moderate-grade cervical intraepithelial neoplasia (CIN1 or 2). | |||||||||||||
Medical condition: Patients with low/moderate-grade cervical intraepithelial neoplasia (CIN1 or 2). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) SK (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017282-35 | Sponsor Protocol Number: 113617 | Start Date*: 2010-07-07 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase IIIb, open, multi-centre gynaecological extension study for the follow-up of a subset of HPV-015 study subjects | ||
Medical condition: GSK Biologicals' HPV-16/18 L1 VLP AS04 vaccine is indicated in females from 10 years of age onwards for the prevention of pre-malignant cervical lesions and cervical cancer causally related to Hum... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Completed) NL (Completed) PT (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-004050-29 | Sponsor Protocol Number: Vvax001-UMCG-02 | Start Date*: 2020-03-30 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: A phase II study to determine the efficacy and safety of Vvax001, a therapeutic Semliki Forest Virus based cancer vaccine, in patients with HPV-16 induced grade 3 cervical intraepithelial neoplasia. | ||
Medical condition: HPV-16 induced pre malignant cervical lesions | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-011617-25 | Sponsor Protocol Number: V503-002 | Start Date*: 2009-10-16 |
Sponsor Name:MSD Finland Oy | ||
Full Title: A Study to Demonstrate Immunogenicity, Tolerability, and Manufacturing Consistency of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered in Preadolescents an... | ||
Medical condition: Cervical Cancer | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FI (Completed) BE (Completed) AT (Completed) SE (Completed) ES (Completed) PL (Completed) Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-005576-28 | Sponsor Protocol Number: VB-C-01 | Start Date*: 2015-07-13 |
Sponsor Name:VACCIBODY A.S. | ||
Full Title: An Exploratory Safety and Immunogenicity Study of Human Papillomavirus (HPV16+) Immunotherapy VB10.16 in Women with High Grade Cervical Intraepithelial Neoplasia (HSIL; CIN 2/3) | ||
Medical condition: High grade cervical intraepithelial neoplasia (HSIL, CIN 2/3) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-006946-24 | Sponsor Protocol Number: NV25025 | Start Date*: 2009-12-10 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A randomized, double blind, placebo controlled, parallel group, multicenter study of the safety and response rate of 3 subcutaneously administered doses of 5x10E7pfu RO5217790 in patients with high... | ||||||||||||||||||
Medical condition: High grade cervical intraepithelial neoplasia grade 2 or 3 associated with High Risk HPV infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) FI (Completed) ES (Completed) BE (Completed) | ||||||||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2016-002761-63 | Sponsor Protocol Number: HPV-301 | Start Date*: 2018-04-16 | ||||||||||||||||
Sponsor Name:Inovio Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY ELECTROPORATION WITH CELLECTRA™ 5PSP FOR THE TREATMENT OF HPV-16 AND/OR H... | ||||||||||||||||||
Medical condition: HPV-16 AND/OR HPV-18 RELATED HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (HSIL) OF THE CERVIX | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) LT (Completed) FI (Completed) DE (Completed) CZ (Prematurely Ended) ES (Completed) PT (Completed) PL (Completed) SK (Completed) BE (Completed) NL (Ongoing) EE (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001342-19 | Sponsor Protocol Number: YHGT-CEV-R1 | Start Date*: 2020-11-13 | |||||||||||
Sponsor Name:Asieris MediTech Co., Ltd. | |||||||||||||
Full Title: A double blind, prospective, randomized, placebo controlled, multi-center phase 3 study to evaluate efficacy and safety of Cevira® in patients with cervical histologic high-grade squamous intraepit... | |||||||||||||
Medical condition: Patients with cervical histologic HSIL. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) SK (Completed) PL (Completed) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004662-33 | Sponsor Protocol Number: C/39/2018 | Start Date*: 2019-07-12 |
Sponsor Name:Imperial College London | ||
Full Title: NOVEL: Nonavalent HPV vaccine after local conservative treatment for cervical pre-invasive disease - a randomised controlled trial | ||
Medical condition: Cervical intra-epithelial neoplasia | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001890-98 | Sponsor Protocol Number: HPV001 | Start Date*: 2020-05-29 | |||||||||||
Sponsor Name:Vaccitech Ltd. | |||||||||||||
Full Title: A Phase 1b/2 Randomised, Placebo-controlled, Dose-ranging Study to Evaluate Safety, Tolerability and Immunogenicity of a Chimpanzee Adenovirus (ChAdOx1)-vectored Multigenotype High Risk Human Papil... | |||||||||||||
Medical condition: Persistent hrHPV infection in participants with low grade cervical lesions | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001334-33 | Sponsor Protocol Number: HPV-003 | Start Date*: 2013-01-09 | |||||||||||
Sponsor Name:Inovio Pharmaceuticals, Inc. | |||||||||||||
Full Title: PHASE II PLACEBO-CONTROLLED STUDY OF VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA VACCINE) DELIVERED IM FOLLOWED BY ELECTROPORATION (EP) WITH CELLECTRA®-5P FOR THE TREATMENT OF BIOPSY-PROVEN CIN 2/3 OR ... | |||||||||||||
Medical condition: Cervical Intraepithelial Neoplasia (CIN) 2/3 or 3 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007763-16 | Sponsor Protocol Number: 1.0 | Start Date*: 2009-05-06 | ||||||||||||||||
Sponsor Name:Medizinische Universität Wien, Univ.Klinik f.Frauenheilkunde,Abt. f.Gynäkologie und Gyn.Onkologie | ||||||||||||||||||
Full Title: Topical Imiquimod in Treating Patients with Grade 2/3 Cervical Intraepithelial Neoplasia | ||||||||||||||||||
Medical condition: Grade 2/3 Cervical Intraepithelial Neoplasia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: AT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-004721-40 | Sponsor Protocol Number: HPV-EU-001 | Start Date*: 2015-04-22 | |||||||||||
Sponsor Name:Genexine, Inc | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-controlled, Multi-Center, Phase 2 Clinical Trial to Evaluate the Efficacy and the Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularl... | |||||||||||||
Medical condition: Cervical Intraepithelial Neoplasia Grade 2 (CIN 2), Grade 2/3 (CIN 2/3) or Grade 3 (CIN3) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: EE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002546-20 | Sponsor Protocol Number: 104820 | Start Date*: 2006-11-02 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase III, double-blind, randomized, controlled study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals’ HPV 16/18 L1/AS04 vaccine administered intramuscularly ac... | ||
Medical condition: For active immunization of girls and women from 10 years of age onwards for the prevention of persistent human papillomavirus (HPV) infections and related clinical outcomes (cytological abnormaliti... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Completed) PT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002764-94 | Sponsor Protocol Number: OZBS82.17204 | Start Date*: 2019-07-29 | ||||||||||||||||
Sponsor Name:Erasmus MC | ||||||||||||||||||
Full Title: Adjuvant vaccination against HPV in surgical treatment of CIN lesions, a Randomised Controlled Trial | ||||||||||||||||||
Medical condition: Human papilloma virus (HPV) causes cervical cancer. HPV vaccination is highly effective in primary prevention. There is less known about a possible secondary effect in women already infected with H... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004114-17 | Sponsor Protocol Number: HPV-303 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:Inovio Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: REVEAL 2: A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation with CELLECTRA™ 5PSP for the Treatment of HPV-1... | ||||||||||||||||||
Medical condition: HPV-16 and/or HPV-18 related high grade squamous intraepithelial lesion (HSIL) of the cervix | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) LT (Completed) EE (Completed) ES (Restarted) PL (Completed) FI (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
